Stiefel Labs Adds Connetics’ Topical Delivery Technology With Acquisition Of Dermatology Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
Completion of the $640 million acquisition combines Stiefel’s dermatology portfolio with Connectics’ patented drug delivery technology.
You may also be interested in...
GSK’s Stiefel Adds Psoriasis/Atopical Dermatitis Candidate In Licensing Deal
For about $34 million, Stiefel gets development and commercialization rights in most of the world to a novel, non-steroidal, topical anti-inflammatory compound in Phase II.
Dermatology Space Waits For Skinny On Stiefel Buyout
Pure dermatology plays abound, but few are big enough to take on privately held Stiefel; where the company will find a fit is anybody’s guess.
Dermatology Space Waits For Skinny On Stiefel Buyout
Pure dermatology plays abound, but few are big enough to take on privately held Stiefel; where the company will find a fit is anybody’s guess.